For individuals living with type 2 diabetes or struggling with weight loss, Rybelsus has become a popular name in the realm of oral GLP-1 receptor agonists. While its effectiveness in lowering blood ...

Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

Discover if eating just 5 specific nuts can actually control hunger all morning long. Science reveals how these ...

What it means for patients - The compounded versions of the drug were originally sold to combat a brand-name shortage ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 ... are safe and tolerable with low risk of hypoglycemia. They are both body weight neutral.

By inhibiting DPP4, vildagliptin causes an increase in glucagon like peptide-1 (GLP-1), an intestinal hormone that aids ... In most studies, the rate of hypoglycemia appeared to be similar to ...

Dr. Ronald Goldenberg, MD, FRCPC, FACE, Endocrinologist, discusses Preventing and Treating Hypoglycemia. The Dallas Wings ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

In a study of adults with diabetes and gastrointestinal (GI) motility abnormalities, over 75% had GI motility abnormalities.

As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, according to data from two European Congress on Obesity abstracts ...